Posts Tagged ‘mi’

Utility of pre-catheterisation high-sensitivity troponin T in patients without obstructive coronary artery disease

Myocardial infarction (MI) in patients subsequently shown to have no obvious, or trivial coronary artery disease (<50% stenosis) at angirography is seldom studied, but may be attributable to either a primary coronary event or, less commonly, type 2 MI. Recently developed, high-sensitivity troponin T (hs-TnT) assays have increased sensitivity for detection of minor degrees of myocardial necrosis, improving MI detection rate. We assessed the prognostic utility of pre-catheterisation hs-TnT in patients without angiographically significant coronary narrowing. Wang, Oh, Samaranayake, Watson, Stewart, Webster, Ruygrok Heart, Lung and Circulation - Volume 23, Supplement 1, e1-e48 Abstract & full-text available.

Elevation of aspartate aminotransferase predicts mortality after coronary artery bypass grafting

Cardiac troponins are the recommended biomarkers for diagnosing myocardial infarction (MI). Since troponins have become widely available, the roles of other less specific biomarkers have been seldom studied. Aspartate aminotransferase (AST) not only correlates with MI, but also with liver injury due to ischaemia or congestion. We assessed whether post-operative AST levels were associated with adverse outcomes after contemporary coronary artery bypass grafting (CABG).

T. Wang, R. Stewart, T. Ramanathan, G. Gamble, H. White
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Diagnosis of myocardial infarction after aortic valve replacement with high-sensitivity troponins

The Universal Definition for type 5 myocardial infarction (MI) applies to coronary artery bypass grafting (CABG), while perioperative MIs for other cardiac surgeries are rarely studied and not specifically defined. We assessed whether high-sensitivity troponin (hs-TnT), with or without concurrent ischaemic changes on electrocardiogram or echocardiogram, predicted mortality and morbidity after aortic valve replacement (AVR).

T. Wang, R. Stewart, T. Ramanathan, D. Choi, G. Gamble, P. Ruygrok, H. White
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

How well are we doing in secondary prevention after myocardial infarction – The STABILITY study experience

Compliance with preventive medications after myocardial infarction is known to be suboptimal in New Zealand (NZ), and to worsen over time. Patients who participate in clinical trials may have better compliance and risk factor control. This study describes achievement of standard of care goals in NZ participants compared to those from the rest of the world in the global STABILITY study. This study evaluated the effects of darapladib on top of best care on cardiovascular death, MI and stroke in high risk patients with established cardiovascular disease.

R. Stewart, J. Benetar, A. Hamer, D. Scott, G. Devom, H. Hart, J. Elliott, J. Tisch, L. Davidson, M. Hills, N. Harrison, R. Rankin, T. O’Meeghan, V. Chen, H. White

Long-term clinical outcome of patient with type I vs type II non-STEMI

Type I (myocardial necrosis from plaque disruption) and type II (myocardial from supply-demand mismatch) are most commonly encountered myocardial infarction (MI). It is unclear if this distinction has important implications on clinical outcome.

A. Kueh, M. Lee, A. Kerr
Counties Manukau District Health, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?